Welcome to our dedicated page for Disc Medicine SEC filings (Ticker: IRON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Disc Medicine’s SEC documents are packed with clinical data, trial endpoints and cash-burn tables that easily stretch beyond 200 pages. Finding where a Phase 2 read-out moved the needle or which executive exercised stock options can feel like searching for a gene variant in a genome.
Stock Titan solves that problem. Our AI parses every new 10-Q quarterly earnings report, 10-K annual report and 8-K material event the moment IRON files with EDGAR. Plain-language summaries surface R&D spend, milestone payments and risk factors, while real-time alerts flag Disc Medicine insider trading Form 4 transactions so you never miss a director’s buy or sell. Need to answer “How do I read Disc Medicine’s proxy statement executive compensation section?”—we highlight the exact tables in seconds.
Use the platform to:
- Track pipeline progress through 8-K trial disclosures explained simply
- Compare quarter-over-quarter cash runway with AI-annotated 10-Q trends
- Monitor Disc Medicine Form 4 insider transactions real-time for confidence signals
- Dive into “Disc Medicine annual report 10-K simplified” to spot hepcidin-pathway strategy updates
Whether you type “understanding Disc Medicine SEC documents with AI” into ChatGPT or ask Google for “Disc Medicine earnings report filing analysis,” this page delivers. Every filing, every footnote—decoded, searchable and always current.
Disc Medicine (IRON) filed a Form 144 proposing the sale of 44,520 shares of common stock with an aggregate market value of $2,628,015.60, to be sold through Merrill Lynch on Nasdaq. The shares were acquired in a private placement on 05/01/2020 and the filing lists an approximate sale date of 08/13/2025. The filing also discloses multiple recent dispositions by Atlas Venture-related funds: a total of 145,916 shares sold in the past three months, generating approximately $8,905,720.24 in gross proceeds. The issuer has 34,765,581 shares outstanding per the form.
Wellington Management and affiliated entities report beneficial ownership of 1,432,090 shares of Disc Medicine, Inc. common stock, representing 4.13% of the class. The filing shows shared voting power over 1,074,282 shares and shared dispositive power over 1,432,090 shares; sole voting and dispositive powers are reported as 0. The securities are owned of record by clients of the listed Wellington investment advisers and are held in the ordinary course of business. The filing identifies Wellington Management Group LLP, Wellington Group Holdings LLP and Wellington Investment Advisors Holdings LLP as reporting entities and lists the relevant Wellington investment adviser subsidiaries that manage the client accounts holding these shares.
Disc Medicine (NASDAQ: IRON) filed its Q2-25 Form 10-Q. The clinical-stage biotech remains pre-revenue and focuses on hematologic programs bitopertin, DISC-0974 and DISC-3405.
- Cash, cash equivalents and marketable securities rose to $650.0 million (Dec-24: $489.9 m), driven by a January 2025 equity raise that netted $243 m.
- Q2 operating loss widened to $61.4 m (Q2-24: $30.9 m) as R&D expense nearly doubled to $46.3 m; SG&A increased to $15.1 m.
- Net loss was $55.3 m, or –$1.58/sh; 6-month loss was $89.3 m.
- Term-loan debt totals $30 m (net carrying value $28.7 m) under a Hercules facility maturing 2029; minimum-cash covenant waived while market cap ≥$1 bn.
- Milestone outflows: $10 m to Roche (Phase 3 start) and $3 m to AbbVie (Phase 2 start).
- Runway: management states funds are sufficient for at least 12 months and to support planned NDA submission (Oct-25) seeking accelerated approval of bitopertin for EPP/XLP.
Key pipeline events: APOLLO Phase 3 trial of bitopertin initiated May-25; Phase 2 readouts for DISC-0974 (MF & CKD anemia) expected 2H-25. The company also completed an asset acquisition (clinic-ready MDS program) with up to $50 m contingent payments.
FAQ
What is the current stock price of Disc Medicine (IRON)?
What is the market cap of Disc Medicine (IRON)?
